Jilin Aodong Pharmaceutical Group Co Ltd

Jilin Aodong Pharmaceutical Group Co Ltd maintains a strong liquidity position, with a current ratio of 2.39, indicating the company can cover its short-term liabilities more than twice over. However, the company has a negative net cash position after subtracting total debt, which introduces a medium liquidity risk. The debt-to-equity ratio is 0.07, suggesting a conservative capital structure with limited leverage. Free cash flow of 1.8 billion CNY supports operational flexibility and potential reinvestment. Profitability metrics show a return on equity of 7.81% and a return on assets of 6.96%, both of which are strong indicators of efficient capital use and asset management. The company's operating income of 2.41 billion CNY and net income of 2.395 billion CNY reflect a healthy margin structure, with gross profit of 1.064 billion CNY contributing to a solid operating margin. These figures suggest the company is performing well relative to industry norms, though specific industry medians are not provided in the data. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification beyond the domestic Chinese market. This concentration increases exposure to local economic and regulatory conditions, which could affect revenue stability. No material revenue is attributed to international operations, and the company does not report segment-specific revenue breakdowns. The company's growth trajectory is not explicitly outlined in the data, but the strong net income and free cash flow suggest a stable and potentially growing business. No specific revenue growth rates or future projections are provided in the input data. The capital expenditure of -128.45 million CNY indicates a reduction in investment in physical assets, which may reflect a shift in strategic focus or a capital conservation strategy. Risk factors include a medium liquidity risk due to the negative net cash position after debt, and a low dilution risk as the number of shares outstanding has not changed between basic and diluted figures. The company's ESG score of 34.66 is below average, with particularly low scores in the Environment and Social pillars, indicating potential reputational and regulatory risks. The Governance pillar score of 74.10 is relatively strong, suggesting better corporate governance practices. Recent events and filings are not detailed in the input data, but the company's ESG controversies score of 100 indicates no recent controversies, which is a positive signal for governance and risk management. No specific recent filings or transcripts are provided to assess management commentary or strategic direction.